MRA is the largest non-profit funder of melanoma research. MRA’s investment in the field has been critical in catalyzing transformative, strategic, and collaborative investments in scientific discovery and translation.
Each year, MRA selects new research awards to address critical unmet needs in melanoma detection, prognostication, and treatment. All grant awards are selected by MRA’s Grant Review Committee through a diligent peer review process and are confirmed by our Board of Directors.
MRA supports both individual investigator and collaborative team projects focused on translational, innovative research that will impact the prevention, diagnosis, staging, and treatment of melanoma in the near and intermediate future.
Learn more about our RFP for pre-clinical, translational, and early clinical research with the potential to produce unusually high impact, near-term advancements in melanoma prevention, detection, diagnosis, and treatment.
The second of three Request for Applications to be released through the Next Steps Program is now open for applications.
MRA encourages applications from a diverse pool of investigators with respect to race, gender, sexual orientation, ethnicity, national origin, and disability. MRA recognizes that diversity in the biomedical research workforce is critical for ensuring that the most creative minds have the opportunity to contribute to realizing our research goals and to ensuring more equitable health outcomes for all.
The Melanoma Research Alliance is recognized by the NIH as meeting approved standards for peer review. Thus, multi-year research programs, excluding pilot projects, funded by MRA are eligible for consideration as part of the research program via the National Institutes of Health P30 Cancer Center Support Grants (CCSG). To qualify for this, MRA has met the specific minimum levels of “peer reviewed, funded research projects.”
Learn more